126 related articles for article (PubMed ID: 36952588)
21. Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma.
Luo D; Liu Y; Lin S; Tan L; Du Z; Long M; Zhu Y; Peng X; Zong W; Mackenzie GG; Li H; Ouyang N
Oncol Rep; 2019 Feb; 41(2):1253-1263. PubMed ID: 30535496
[TBL] [Abstract][Full Text] [Related]
22. Has_circ_0008274 promotes cell proliferation and invasion involving AMPK/mTOR signaling pathway in papillary thyroid carcinoma.
Zhou GK; Zhang GY; Yuan ZN; Pei R; Liu DM
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8772-8780. PubMed ID: 30575918
[TBL] [Abstract][Full Text] [Related]
23. [The study of the correlation of papillary thyroid carcinoma's invasion toward Ezrin and E-cadherin].
Liu C; Chen X; Gao Z; Liu Z; Tao X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Sep; 26(17):789-91, 795. PubMed ID: 23214316
[TBL] [Abstract][Full Text] [Related]
24. Younger Than 55 Years Old and
Lai Y; Gu Y; Yu M; Deng J
Int J Gen Med; 2023; 16():1403-1414. PubMed ID: 37155469
[TBL] [Abstract][Full Text] [Related]
25. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.
Silver JA; Bogatchenko M; Pusztaszeri M; Forest VI; Hier MP; Yang JW; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2021 Nov; 50(1):63. PubMed ID: 34742355
[TBL] [Abstract][Full Text] [Related]
26. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
27. Predicting factors of central lymph node metastasis and BRAF
Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF
World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769
[TBL] [Abstract][Full Text] [Related]
28. Expression of HIF-1α/PKM2 axis correlates to biological and clinical significance in papillary thyroid carcinoma.
Hao Z; Wang Y; Li J; Liu W; Zhao W; Wang J
Medicine (Baltimore); 2023 Mar; 102(10):e33232. PubMed ID: 36897686
[TBL] [Abstract][Full Text] [Related]
29. Association of Body Mass Index With Clinicopathological Features of Papillary Thyroid Carcinoma: A Retrospective Study.
Dong Z; Liu W; Su F; Cheng R
Endocr Pract; 2023 Feb; 29(2):83-88. PubMed ID: 36481471
[TBL] [Abstract][Full Text] [Related]
30. ALDH5A1 acts as a tumour promoter and has a prognostic impact in papillary thyroid carcinoma.
Deng XY; Gan XX; Feng JH; Cai WS; Wang XQ; Shen L; Luo HT; Chen Z; Guo M; Cao J; Shen F; Xu B
Cell Biochem Funct; 2021 Mar; 39(2):317-325. PubMed ID: 32881051
[TBL] [Abstract][Full Text] [Related]
31. Minimal extrathyroidal extension is associated with lymph node metastasis in single papillary thyroid microcarcinoma: a retrospective analysis of 814 patients.
Song RY; Kim HS; Kang KH
World J Surg Oncol; 2022 May; 20(1):170. PubMed ID: 35643530
[TBL] [Abstract][Full Text] [Related]
32. Knockout of ASAP1 induces autophagy in papillary thyroid carcinoma by inhibiting the mTOR signaling pathway.
Jiang N; Yang Y; Zhao G; Yuan Q; Liu Z; Wang X; Geng Z; Jia M; Zheng J; Lu X; Yue J; Fan Y
Pathol Res Pract; 2020 Jun; 216(6):152950. PubMed ID: 32307199
[TBL] [Abstract][Full Text] [Related]
33. [Expression and clinical significance of Nrf2 and ERK pathway in papillary thyroid carcinoma].
Chen YM; Wei L; Lin X; Zhang WJ; Wu JF; Xue G
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 31(12):941-945. PubMed ID: 29798417
[No Abstract] [Full Text] [Related]
34. Low urinary iodine is a protective factor of central lymph node metastasis in papillary thyroid cancer: a cross-sectional study.
Zeng Z; Li K; Wang X; Ouyang S; Zhang Z; Liu Z; Sun J; Ye X; Kang W; Yu J
World J Surg Oncol; 2021 Jul; 19(1):208. PubMed ID: 34253203
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma.
Dong Y; Wang D; Luo Y; Chen L; Bai H; Shen Y; Zhang Y; Chen X; Su X; Zhao J; Liu H; Lu J; Yao Z; Zhao Y; He C; Li X
Oncol Lett; 2021 Mar; 21(3):188. PubMed ID: 33574927
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma.
Kim WY; Kim HY; Son GS; Bae JW; Lee JB
J Cancer Res Ther; 2014; 10(1):50-5. PubMed ID: 24762486
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic pseudogene DUXAP10 knockdown suppresses proliferation and invasion and induces apoptosis of papillary thyroid carcinoma cells by inhibition of Akt/mTOR pathway.
Li J; Jiang L; Liu Z; Li Y; Xu Y; Liu H
Clin Exp Pharmacol Physiol; 2020 Aug; 47(8):1473-1483. PubMed ID: 32215944
[TBL] [Abstract][Full Text] [Related]
38. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
40. [Correlation between Ultrasound-guided Fine-needle Aspiration Combined with BRAF
Zhang Y; Luo YK; Zhang Y; Zhang MB; Guang Y; Xie F; Jiang B; Tang J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Aug; 41(4):517-523. PubMed ID: 31484615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
